HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch
Section

Pipeline

Late-stage drugs with significant commercial implications

FDA approves once-daily HIV pill from Merck
PipelineEndpoints News ↗
A new HIV treatment will soon come to market, and it will spearhead Merck’s attempt to be one of the leading d…
Apr 21, 2026
STAT+: At AACR, a provocative use of CAR-T, Merck’s new thing and cancer’s geography problem
PipelineSTAT News ↗
At AACR, a bold use of CAR-T raises hopes and provocative questions about its use in smoldering multiple myelo…
Apr 20, 2026
Merck Gains EU Clearance for Enflonsia, a Long-Acting RSV Antibody for Infants
PipelineBriefing
Enflonsia, now cleared across the EU and EEA, promises single-dose, five-month protection against RSV, positio…
Apr 20, 2026
What actually drives speed in complex drug development programs
PipelineBioPharma Dive ↗
Learn how early coordination across functions, phases and partners can reduce risk and accelerate drug develop…
Apr 20, 2026
STAT+: AACR 2026: More strong data for Revolution Medicines’ KRAS drug
PipelineSTAT News ↗
You're reading the web version of STAT's popup newsletter, AACR in 30 seconds, your guide to what's happening …
Apr 19, 2026
Small pools, big ideas: How the rare disease community is reimagining clinical trials
PipelineFierceBiotech ↗
The traditional gold standard of clinical trials with a randomized, placebo-controlled design involving hundre…
Apr 17, 2026
← Newer Page 12 Older →
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.